164 related articles for article (PubMed ID: 11883527)
1. Treatment of Epstein-Barr virus-associated malignancies with specific T cells.
Gottschalk S; Heslop HE; Roon CM
Adv Cancer Res; 2002; 84():175-201. PubMed ID: 11883527
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Epstein-Barr virus-associated cancers in children.
Straathof KC; Bollard CM; Rooney CM; Heslop HE
Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy for EBV-associated malignancies.
Gottschalk S; Heslop HE; Rooney CM
Leuk Lymphoma; 2005 Jan; 46(1):1-10. PubMed ID: 15621775
[TBL] [Abstract][Full Text] [Related]
4. Adoptive cell therapy against EBV-related malignancies: a survey of clinical results.
Merlo A; Turrini R; Dolcetti R; Zanovello P; Amadori A; Rosato A
Expert Opin Biol Ther; 2008 Sep; 8(9):1265-94. PubMed ID: 18694349
[TBL] [Abstract][Full Text] [Related]
5. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
Davis JE; Moss DJ
Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic strategies for EBV-associated malignancies.
Khanna R; Tellam J; Duraiswamy J; Cooper L
Trends Mol Med; 2001 Jun; 7(6):270-6. PubMed ID: 11378517
[TBL] [Abstract][Full Text] [Related]
7. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.
Paludan C; Münz C
Curr Mol Med; 2003 Jun; 3(4):341-7. PubMed ID: 12776989
[TBL] [Abstract][Full Text] [Related]
8. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
Sun Q; Burton R; Reddy V; Lucas KG
Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
[TBL] [Abstract][Full Text] [Related]
9. T cell recognition of Epstein-Barr virus associated lymphomas.
Rickinson AB; Murray RJ; Brooks J; Griffin H; Moss DJ; Masucci MG
Cancer Surv; 1992; 13():53-80. PubMed ID: 1330300
[TBL] [Abstract][Full Text] [Related]
10. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
[TBL] [Abstract][Full Text] [Related]
11. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells.
Rooney CM; Roskrow MA; Suzuki N; Ng CY; Brenner MK; Heslop H
Ann Oncol; 1998; 9 Suppl 5():S129-32. PubMed ID: 9926252
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
13. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
[TBL] [Abstract][Full Text] [Related]
14. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Epstein-Barr virus-associated cancers.
Rooney CM; Roskrow MA; Smith CA; Brenner MK; Heslop HE
J Natl Cancer Inst Monogr; 1998; (23):89-93. PubMed ID: 9709309
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for EBV-associated malignancies.
Merlo A; Turrini R; Dolcetti R; Zanovello P; Rosato A
Int J Hematol; 2011 Mar; 93(3):281-293. PubMed ID: 21336546
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
[TBL] [Abstract][Full Text] [Related]
18. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
[TBL] [Abstract][Full Text] [Related]
19. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
Wagner HJ; Bollard CM; Vigouroux S; Huls MH; Anderson R; Prentice HG; Brenner MK; Heslop HE; Rooney CM
Cancer Gene Ther; 2004 Feb; 11(2):81-91. PubMed ID: 14685154
[TBL] [Abstract][Full Text] [Related]
20. T cell therapies.
Gottschalk S; Bollard CM; Straathof KC; Louis CU; Savoldo B; Dotti G; Brenner MK; Heslop HE; Rooney CM
Ernst Schering Found Symp Proc; 2006; (4):69-82. PubMed ID: 17824182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
